We are live on ! Find out more
GYRE icon

Gyre Therapeutics

58 hedge funds and large institutions have $73.1M invested in Gyre Therapeutics in 2026 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 18 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

938% more capital inflows, than outflows

Capital inflows: $9.6M | Capital outflows: $922K

28% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 18

1.16% more ownership

Funds ownership: 7.78% → 8.95% (+1.2%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2% less funds holding

Funds holding: 59 → 58 (-1)

13% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 8

Holders
58
Holders Change
-1
Holders Change %
-1.69%
% of All Funds
0.71%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
7
Increased
23
Reduced
18
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

GYRE Hedge Fund Activity: Q3 2026 in Review

58 of the 8,208 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q3 2026, worth a combined $73.1M — up 28% from $57.2M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of GYRE and 7 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 23 added.

The largest buyer was Vanguard Capital Management, adding an estimated $3.93M. The largest seller was Goldman Sachs, cutting an estimated $175K.

  • 58 institutional investors held Gyre Therapeutics (GYRE) as of Q3 2026, down from 59 in Q2 2026.
  • Funds reported $73.1M of Gyre Therapeutics stock for Q3 2026, up 28% quarter-over-quarter.
  • 7 funds opened new Gyre Therapeutics positions in Q3 2026 and 8 closed out, a net change of -1 holder.
  • The largest Gyre Therapeutics buyer in Q3 2026 was Vanguard Capital Management, an estimated $3.93M added.
  • The largest Gyre Therapeutics seller in Q3 2026 was Goldman Sachs, an estimated $175K sold.

Based on aggregated 13F filings for Q3 2026.